Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 31 | 2024Trinity Biotech Acquires Waveform CGM Assets; Novartis Q4 ’23 Earnings; Abbott Launches Nutrition Drink for Weight LossPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Jan 31 | 2024New Novo Once-Monthly Dual-Agonist; Icodec Delayed; Novo Q4 ’23 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other Jan 30 | 2024New Insulin Patch Pump; Pfizer Q4 ‘23 Earnings; Lilly Initiates Ph2 LA Amylin Obesity Trial; Lilly Trying to Get Mounjaro Reimbursed in GermanyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Jan 29 | 2024Roche Completes Carmot AcquisitionPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Jan 25 | 2024Mounjaro KwikPen Approved in UK; Biocorp Receives 510(K) Clearance for SoloSmart; Novo Initiates Second Ph3 Cagrisema T2DM Trial; Mounjaro 12.5mg Added to FDA Shortage Database; Counterfeit Ozempic Causes Cases of HypoglycemiaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery Jan 24 | 2024Abbott Q4 ‘23 Earnings; Sciwind Oral GLP-1RA Ph1 DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Jan 23 | 2024Novo Partners for Oral Obesity Asset; Scholar Rock Announces IND Clearance for Obesity; JNJ Q4 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, SGLT2i Jan 22 | 2024SELECT up for CHMP Opinion?; January CHMP Agenda; Akero Initiates Ph3 EFX MASH TrialPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jan 19 | 2024Dexcom to Build EU Manufacturing Plant; FDA Finds Manufacturing Lapses at Lilly PlantPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring Jan 17 | 2024Lilly to Launch Mounjaro in EU; FDA Posts Libre 3 Android App Recall; Novo Initiates Ph1 Cagrisema Study in Weight Loss MechanismsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 16 | 2024Novo Resumes Shipments of Wegovy doses in US; Amgen to Acquire Cytokinetics?; Dexcom G7 Integrated with t:slim X2 OUS; Novo Initiates Additional Ph3 Ziltivekimab Trial in HF; BI Expands Greece Manufacturing FacilityPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Jan 11 | 2024JPM 2024 Day 4: MDGL, LXRX, MNKD, AKBA, and XERS; Novartis No Longer Pursuing Cytokinetics AcquisitionPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Jan 10 | 2024JPM 2024 Day 3: TRNS, ESPR, IONS, AMRN, EMBC, and VTRSPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 10 | 2024JPM 2024 Day 2: ABT, PODD, NVO, LLY, AZN, BAY, BMF, TDOC; Embecta Files 510(k) for T2DM Patch Pump; Omada Partners with Amazon for Cardiometabolic ProgramsPurchase Blast$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 08 | 2024JPM 2024 Day 1: DXCM, MDT, AMGN, AKERO, ARWR, CYTO, NVS, VRTX, ALN, REGN; Tandem X2 Control-IQ Integrated with Libre 2 Plus; Supersapiens Launches Diabetes Platform; Novo Ph3 Icosema ResultsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Jan 05 | 2024Lilly Initiates Orforglipron vs. Farxiga Ph3 Trial; Fractyl Selects its Rejuva GLP-1 Gene Therapy; Tiziana Files Patent for Foralumab + GLP-1RA; Merck GLP-1RAs Commentary; Rivus Completes HFpEF Ph2a EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Jan 04 | 2024Roche Restructures Diabetes Business; Novo Partners for Obesity and MASH; BI Partners with Ribo for MASH; Lilly Issues Open Letter on Off-Label Mounjaro/Zepbound Use; Lilly Launches Diabetes/Obesity Digital Health Program; Evaluate Projects Novo and Lilly to Top 2024 Global New SalesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jan 03 | 2024Senseonics Provides Implantable CGM Updates; Esperion and Daiichi Sankyo Resolve Litigation; Better Therapeutics and Glooko Partner for AspyreRxPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Jan 02 | 2024Holiday Hangover: FDA Issues Dasiglucagon CRL for CHI; Cytokinetics Ph3 Aficamten Results; NeuroBo Submits Obesity IND; New O5 Algorithm Trial Observed; Tirzepatide in T1DM Trial; Novo Warns Against Counterfeit Ozempic in US; Glucotrack Preclinical Implantable CGM DataPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Dec 21 | 2023Lilly Partners for Obesity Drug Discovery; Embecta GLP-1RA CommentaryPurchase Blast